|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
The RNA helicase DHX33 is required for cancer cell proliferation in human glioblastoma and confers resistance to PI3K/mTOR inhibition.
|
30552990 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
These data support the notion that disruption of DHX33 function could be an important application for cancer therapy.
|
31182639 |
2019 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
We and others further discovered that DHX33 is strongly expressed in several types of human cancers and plays important roles in promoting cancer cell proliferation.
|
29870660 |
2019 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
We and others further discovered that DHX33 is strongly expressed in several types of human cancers and plays important roles in promoting cancer cell proliferation.
|
29870660 |
2019 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
The RNA helicase DHX33 is required for cancer cell proliferation in human glioblastoma and confers resistance to PI3K/mTOR inhibition.
|
30552990 |
2019 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
These data support the notion that disruption of DHX33 function could be an important application for cancer therapy.
|
31182639 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Overall, our results implicate the important role for DHX33 in Myc-induced cancer and point toward its potential therapeutic value in Myc driven cancers.
|
28498893 |
2017 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Overall, our results implicate the important role for DHX33 in Myc-induced cancer and point toward its potential therapeutic value in Myc driven cancers.
|
28498893 |
2017 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
However, the role of DHX33 in human cancer is rarely studied.
|
27073163 |
2016 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Forced reduction of DHX33 in these cancer cells abolished tumor formation in vivo Our study demonstrates for the first time that DHX33 acts as a direct transcriptional regulator to promote cell cycle progression and plays an important role in driving cell proliferation during both embryo development and tumorigenesis.
|
27601587 |
2016 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Forced reduction of DHX33 in these cancer cells abolished tumor formation in vivo Our study demonstrates for the first time that DHX33 acts as a direct transcriptional regulator to promote cell cycle progression and plays an important role in driving cell proliferation during both embryo development and tumorigenesis.
|
27601587 |
2016 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
However, the role of DHX33 in human cancer is rarely studied.
|
27073163 |
2016 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Elevated DHX33 protein is pivotal for c-Myc to drive tumor formation.
|
28498893 |
2017 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Forced reduction of DHX33 in these cancer cells abolished tumor formation in vivo Our study demonstrates for the first time that DHX33 acts as a direct transcriptional regulator to promote cell cycle progression and plays an important role in driving cell proliferation during both embryo development and tumorigenesis.
|
27601587 |
2016 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
In a cohort of 520 patients, DHX33 expression in HCC was closely associated with tumor size (P = 0.007), serum AFP level (P = 0.011), and tumor capsule (P = 0.030).
|
27073163 |
2016 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
miR-634 exhibits anti-tumor activities toward hepatocellular carcinoma via Rab1A and DHX33.
|
27693040 |
2016 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our data therefore suggest DHX33 is overexpressed in HCC and serves as a promising prognostic biomarker for this deadly disease.
|
27073163 |
2016 |
|
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Additionally, DHX33 was found to be induced by inhibitors of PI3K and mTOR whose activation has been detected in 50% of glioblastoma.
|
30552990 |
2019 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Additionally, DHX33 was found to be induced by inhibitors of PI3K and mTOR whose activation has been detected in 50% of glioblastoma.
|
30552990 |
2019 |
|
Childhood Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Additionally, DHX33 was found to be induced by inhibitors of PI3K and mTOR whose activation has been detected in 50% of glioblastoma.
|
30552990 |
2019 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
DHX33 probably functions as a critical regulator to promote GBM development.
|
30552990 |
2019 |
|
Lymphoma, Non-Hodgkin
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
DHX33 protein was overexpressed in a certain subset of human non-Hodgkin's lymphoma tissues.
|
28498893 |
2017 |
|
Adult Non-Hodgkin Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
DHX33 protein was overexpressed in a certain subset of human non-Hodgkin's lymphoma tissues.
|
28498893 |
2017 |
|
Childhood Non-Hodgkin Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
DHX33 protein was overexpressed in a certain subset of human non-Hodgkin's lymphoma tissues.
|
28498893 |
2017 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
DHX33 protein was overexpressed in a certain subset of human non-Hodgkin's lymphoma tissues.
|
28498893 |
2017 |